

1 **Research Article**

2 **Molecular Profiling of Breast Cancer Susceptibility of Obese or Insulin-**  
3 **Resistant and Pre-Diabetic Patients Using *ITLN1* and *CD295* SNPs**

4 Nadia M. Hamdy <sup>1\*</sup> and Reham A. El-Shemy <sup>2</sup>

5 <sup>1</sup> Biochemistry Department, Faculty of Pharmacy, Ain Shams University, Abassia,  
6 11566, Cairo, Egypt, <sup>2</sup> Department of Clinical Pathology, National Cancer Institute,  
7 Cairo University, Egypt

8 **\*Corresponding author:** Dr. Nadia M. Hamdy, Prof. of Biochemistry, Biochemistry  
9 Department, Faculty of Pharmacy, Ain Shams University, Abassia, Monazamat Al-  
10 Wahda Al-Afriqia st., 11566, Cairo, Egypt. Email: [nadia\\_hamdy@pharma.asu.edu.eg](mailto:nadia_hamdy@pharma.asu.edu.eg)

11 **Running head:** Inflammation/obesity genes SNPs & DNA damage in BC.

12

13 **Remarks/Highlights.**

14 • *ITLN1* and *CD295* polymorphism testing might be utilized for accessing BC  
15 susceptibility in either obese or insulin resistant, pre-diabetic patients.

16 • A modestly increased risk of BC in women harboring the C allele of *CD295*  
17 rs6700986 polymorphism and the T allele of the *ITLN1* rs952804, where:

18 1- Tumor clinical stage T II and positive LN involvement as well as the tumor  
19 histologic grade III, obesity existence, pre-diabetic event and being diabetic as well  
20 as IR cases were associated with *CD295* rs6700986 mutant homozygous (CC) and  
21 heterozygous (CT) genotype and *ITLN1* rs952804 mutant heterozygous cases (CT)  
22 ( $P \leq 0.05$ ).

23 2- Tail DNA (%) and tail moment unit were significantly associated with *CD295*  
24 rs6700986 CT genotype and *ITLN1* rs952804 TT. These SNPs could be considered  
25 as BC associated risk factor.

**NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

**Hamdy and El-Shemy 2020**

- 26 • In dominant effect of the C allele (CT+CC vs TT) and the T allele (TT+CT vs CC)  
27 for *CD295* rs6700986 and *ITLN1* rs952804, respectively, were associated with BC  
28 events and risk ( $P \leq 0.05$ ).
- 29 • *CD295* rs6700986 and *ITLN1* rs952804 SNPs may be considered BC-associated  
30 risk for G3, T2, +LN, obesity, pre-diabetic/diabetic and IR in BC patients.

31

32 **Abstract:**

33 Mutations in cluster of differentiation (CD) 295 gene, encoding class I cytokine  
34 receptor, are associated with obesity and breast cancer (BC). SNPs in the adipocyte-  
35 inferred novel cytokine intelectin 1 (ITLN1) remain understudied in connection to  
36 *CD295* polymorphisms and diabetes mellitus (DM) or a pre-diabetic state, as well as  
37 to DNA damage seen in BC. We will explore whether *CD295* (ID rs6700896) and  
38 *ITLN1* (rs rs952804) SNPs impact BC with or without DM, insulin resistance (IR) or  
39 obesity. Effects of *ITLN1* or *CD295* polymorphism(s) on DNA damage in BC were  
40 also examined. Blood samples from 170 women with BC (including 33 and 48 with  
41 DM and pre-diabetes, respectively) and from 108 age-matched women in the control  
42 group were collected. Plasma insulin, leptin, *CD295*, and *ITLN1* levels were  
43 measured by ELISA. DNA damage was assessed using an alkaline comet assay.

44 BC cases with clinical stage T II and positive LN as well as tumor histologic grade  
45 III, presence of obesity, pre-diabetic events, DM or IR were associated with *CD295*  
46 rs6700986 mutant homozygous (CC) and heterozygous (CT) genotype and *ITLN1*  
47 rs952804 mutant heterozygous genotype (CT) ( $P \leq 0.05$ ). Tail DNA (%) and tail  
48 moment units were significantly associated with *CD295* rs6700986 CT and *ITLN1*  
49 rs952804 TT genotypes. C allele (CT+CC vs. TT) and T allele (TT+CT vs. CC) for  
50 *CD295* rs6700986 and *ITLN1* rs952804, respectively, were associated with BC risk

Hamdy and El-Shemy 2020


51 (P ≤ 0.05). *ITLN1* (rs952804) and *CD295* (rs6700986) SNPs should be considered as  
52 BC associated-susceptibility risk factors in obese, insulin resistant, or pre-diabetics.

53

54 **Key words:** *CD295*; cytokines/inflammation; breast cancer;  
55 polymorphism/mutations; *ITLN1*; obesity/Insulin resistance/Diabetes mellitus.

56

57 **Graphical Abstract.**



61        **1. BACKGROUND**

62        Breast cancer (BC) is a very common cancer (Ibrahim et al 2014, Adeloye et al 2018).  
63        BC cases that have high levels of immune cells and/or elevated levels of pro-  
64        inflammatory cytokines are anticipated to have a poor prognosis (Stender et al 2017).  
65        Adipokines are proteins secreted by adipose tissue that are involved in a wide range  
66        of processes, including insulin sensitivity (Miehle et al 2012). A large body of  
67        evidence has supported the role of adipose tissue in the regulation of insulin resistance  
68        (IR). Meanwhile, adipocytokines, which are adipocyte-derived hormones, have also  
69        been implicated in the regulation of metabolism and IR. The protein encoded by the  
70        cluster of differentiation (*CD*)295 gene belongs to a family of cytokine receptors.  
71        There are more than 50 cytokines in the adipokine family, including CD295, a class I  
72        cytokine receptor, which play roles in malignancy in obese individuals (Vona-Davis  
73        and Rose 2007). Long chain CD295 receptor type b is responsible for most of the  
74        effects mediated by CD295 (Laschober et al 2009). CD295 is known to stimulate  
75        gene transcription by activating the cytosolic JAK-STAT proteins MAPK, PI3K, and  
76        AMPK (Mahmoudi et al 2015). CD295 is also a receptor for leptin, an adipocyte-  
77        specific hormone that regulates body weight, and is involved in regulating  
78        metabolism in adipose tissues, as well as in a novel hematopoietic pathway that is  
79        required for normal lymphopoiesis. The adipocyte-inferred cytokine intelectin 1  
80        (*ITLN1*) is a novel secretory and galactose-binding lectin that appears to have an anti-  
81        inflammatory role in both obesity (Jamshidi et al 2017) and inflammation-related  
82        diseases (Huang et al 2016), including BC. The *ITLN1* gene product omentin1 is  
83        mainly expressed in visceral adipose tissue, and was shown to inhibit inflammatory  
84        responses and mitigate IR as well as other obesity-related disorders (Du et al 2016).  
85        An immediate relationship between obesity and increased risk of BC has been

**Hamdy and El-Shemy 2020**

86 reported (Imayama et al 2013). The relationship of BC to inflammation and obesity  
87 suggests that polymorphisms in the CD295 and/or *ITLNI* genes, which both play roles  
88 in adipose tissues, could occur BC. Moreover, hyperinsulinemia actuates proliferative  
89 tissue anomalies, due to the strong anabolic impact of insulin, which stimulates DNA  
90 synthesis and cell proliferation (Boyd 2003). Increased IR promotes elevated glucose  
91 levels that can be specifically cytotoxic and pro-inflammatory (Nasiri et al., 2019), as  
92 well as oxidatively stressful, and thus could be associated with DNA damage (Ibarra-  
93 Drendall et al 2011).

94 This study was conducted to determine whether single nucleotide polymorphisms  
95 (SNPs) in *CD295* (ID rs6700896) and *ITLNI* (rs rs952804) confer risk for metabolic  
96 disorders (IR and/or DM) in female BC patients in Egypt. The first aim of this study  
97 was to explore how these SNPs affect BC in the presence or absence of diabetes,  
98 insulin resistance, or obesity, whereas the second aim was to examine DNA damage  
99 in these patients using a comet test to detect DNA strand breaks in individual cells  
100 from mononuclear cells isolated from blood samples (Galardi et al 2012). Realizing  
101 that no study inspected the relationship of polymorphisms in these genes with the  
102 level of DNA damage in BC cases, this will be the first main study to do this  
103 examination.

## 104 **2. SUBJECTS, MATERIALS, AND METHODS**

### 105 **2.1. Subjects**

106 This is a retrospective randomized single-center study, composed of patients treated  
107 with chemotherapy for inflammatory BC at a University center (National Cancer  
108 Institute (NCI), Cairo) between January 2015 and December 2015. The study protocol  
109 was approved by the ethical committees of the Faculty of Pharmacy, Ain Shams  
110 University (code number 30/7/2016-F-EBD-01-03) and the NCI, Cairo University,

111 Cairo, Egypt. The study was carried out in accordance with the regulations and  
112 recommendations of the Declaration of Helsinki (WMA 2013). Written informed  
113 consent was obtained from all study subjects.

#### 114 ***2.1.1. Inclusion criteria***

115 Females diagnosed with invasive ductal carcinoma (IDC) for the first time at age 43  
116 or older were included. A total of 170 postmenopausal female patients aged 43-75  
117 were selected and the median age was 53 years-old.

#### 118 ***2.1.2. Exclusion criteria***

119 Patients having incomplete data or histopathologic diagnosis, as well as patients with  
120 metastasis at the time of initial diagnosis were excluded. Males with BC were  
121 excluded as were BC types other than IDC. Other exclusion criteria were: previous or  
122 current history of acute or chronic viral hepatitis; malignant disease; acute infections;  
123 pituitary, adrenal, thyroid, or pancreatic disease, or evidence of any other endocrine  
124 disorders; or prolonged use of corticosteroids or sex hormones.

#### 125 ***2.1.3. Control group***

126 A group of 108 age-matched healthy controls (median age 53 years) with normal liver  
127 enzyme levels and no clinical or laboratory evidence of BC was recruited during  
128 routine wellness examinations.

#### 129 ***2.1.4. Participant data***

130 The demographic characteristics of the study subjects are summarized in Table 1a.  
131 Clinical data were obtained using medical records and original pathology reports and  
132 were compiled in an Excel database (Microsoft Corporation, Redmond, WA, USA).  
133 The following parameters were assessed: patient age, tumor size (defined as  
134 sonographic diameter (mm) on diagnosis), initial tumor stage and nodal status  
135 according to TMN classification, histologic subtype, estrogen receptor status,

**Hamdy and El-Shemy 2020**

136 progesterone status, HER2 status (a score of 0 to +1 was regarded as HER2 negative  
137 and a score of +3 as positive), grading and proliferation status as assessed by Ki-67  
138 staining, and chemotherapy regimen (doxorubicin/trastuzumab/lapatinib). All  
139 histopathological parameters included were derived from the original pathology  
140 reports. Scoring was performed by a specialized pathologist at the Pathology  
141 Department, NCI, Cairo University, according to standardized protocols.

## 142 **2.2. Blood sample collection and preparation**

143 A 7 mL blood sample was collected from each patient into 10 mL K<sub>3</sub>EDTA  
144 vacutainer tubes at the end of the clinical examination interview. Samples were  
145 stored at -80 °C until biochemical assessment at the Research Lab in the Biochemistry  
146 Department, Faculty of Pharmacy, Ain Shams University. One part of the sample was  
147 used for DNA extraction from the blood and was carried out using the QIAamp DNA  
148 Mini Kit protocol (QIAGEN, Inc., Santa Clarita, CA, USA). The extracted DNA was  
149 stored at -80 °C until use in SNP assays. The remaining sample was used for in comet  
150 assays.

### 151 **2.2.1. Biochemical analysis**

152 ELISA was used to determine plasma insulin, leptin, CD295, and ITLN1 levels as  
153 well as CEA, CA15.3, luteinizing hormone (LH), and follicle stimulating hormone  
154 (FSH) according to the manufacturers' instructions. Homeostasis model assessment  
155 (HOMA), a measure of IR, was calculated as:  $[(\text{FBG} \times \text{fasting insulin})/22.5]$   
156 (Mathews et al 1985). This value is regarded as a simple, inexpensive, and reliable  
157 surrogate measure of IR, whereas the HOMA of  $\beta$ -cell function (HOMA-B) index,  
158 computed as the product of 20 and basal insulin levels divided by the value of basal  
159 glucose concentrations minus 3.5, is accepted as a good measure of  $\beta$ -cell function  
160 (Wallace et al 2004).

161                    **2.3.            Genetic analysis**

162    Genotyping was performed using Assays-by-Design supplied by Applied Biosystems  
163    International (ABI) (Applied Biosystems, Foster City, CA). Reactions were  
164    performed on a 7500 ABI Sequence Detection System. The *CD295* rs6700986  
165    polymorphism is a T/C (FWD) single-nucleotide variation on human chromosome  
166    1:180452403,                    p31.3,                    Ancestral                    Allele:                    C.  
167    GAGAATCACTTGAAACCTAGGAGGC[T/C]AAGGTTGTGGTGAGCCGAGAT  
168    CATG, Gene: ACBD6 (GeneView), Functional Consequence: intron variant, Global  
169    MAF:T=0.4603/2305. The *ITLN1* rs952804 polymorphism is a C/T (FWD) single-  
170    nucleotide variation on human chromosome 1:160874955, q23.3, Ancestral Allele: C.  
171    CCACCTGCAGCTTTAGAATTGGGTT[C/T]ATCTGTCTTCTCTATCACTTCTTT  
172    A, Global MAF:T=0.4335/2171. SNPs (<http://www.ncbi.nlm.nih.gov/snp/?term=>)  
173    were chosen based on a minor allele frequency that exceeded 5%.

174                    **2.3.1.    Genotyping and single nucleotide polymorphism (SNP)**

175    SNP genotyping was performed using the TaqMan<sup>®</sup> method for allele-specific  
176    detection (ABI), which involves real-time PCR amplification with fluorescence  
177    detection (Heid et al 1996). The experiments were performed using an ABI Prism<sup>®</sup>  
178    Sequence Detection System (ABI) and TaqMan<sup>®</sup> Universal PCR Master Mix (ABI)  
179    together with 20 ng genomic DNA template (10 ng/μl). Each 25 μl reaction volume  
180    contained 100 ng genomic DNA, 0.2 mM dNTPs, 20 mM Tris-HCl (pH 8.8), 10 mM  
181    KCl, 10 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 2 mM MgSO<sub>4</sub>, 0.1% Triton X-100, and 1 unit *Taq*  
182    polymerase (New England BioLabs). PCR amplification conditions were as follows:  
183    an initial denaturation step at 94 °C for 5 min followed by 34 cycles of 30 sec at 94  
184    °C; 45 sec at 60 °C and 45 sec at 72 °C; and a final elongation at 72 °C for 10 min.

185 After PCR amplification, we performed an endpoint plate read using an ABI StepOne  
186 Plus Real-Time PCR System.

#### 187 **2.4. Comet assay**

188 Alkaline comet assays were performed according to a standard protocol (Singh et al.,  
189 1988; Comet assay kit, Trevigen). DNA migration in peripheral blood leukocytes was  
190 measured using a computer-based image analysis system (COMET IV software,  
191 Perceptive) connected to a camera (Leica DFC340 FX). The supplied software  
192 computed all major measurement parameters, including tail length, which describes  
193 the distance from the center of the nucleoid mass to the distal tail end, tail intensity  
194 (TI): the relative fluorescence intensity of the comet tail that is a measure of the  
195 percentage of DNA in the tail, and tail moment unit (TMU): essentially the product  
196 of tail length and TI.

#### 197 **2.5. Statistical analysis**

198 All statistical analyses were conducted using the SPSS statistical package for  
199 Windows Version 22.0 (SPSS Software, Chicago, IL, USA). First, we tested the  
200 normal distribution of the data in which the results for continuous variables were  
201 expressed as mean  $\pm$  standard deviation (SD) in addition to the median (range) for  
202 nonparametric data. To study the association between variables an odds ratio (OR)  
203 was calculated. For categorical variables, a Chi-square test was used to make  
204 comparisons between different groups. The best cutoff values for the investigated  
205 parameter(s) (FSH) were calculated from ROC curves. Genetic analyses were also  
206 conducted using unconditional logistic regression. Initially, we used univariate  
207 analyses to examine possible associations between each polymorphism and cancer  
208 grades (II and III) or T (I and II) or N (-/+), or DNA damage and associated metabolic  
209 factors (e.g., insulin, HOMA-IR, and IR). We also conducted subgroup analyses to

210 examine potential interactions by the levels of the pre-specified factors and the  
211 studied SNPs. Based on the findings from our population, we computed the  
212 frequencies of each allele using Hardy-Weinberg equilibrium (HWE) and online  
213 software. A likelihood ratio test was performed to test significances. Correlations  
214 were assessed using the Spearman correlation coefficient ( $r$ ). Two-tailed analyses  
215 were performed, and  $P$  values  $\leq 0.05$  were considered statistically significant.

### 216 **3. RESULTS**

217 A total of 278 individuals were recruited for this study, including 170 females with  
218 BC, of whom 158 were insulin resistant (Table 1a). Among the BC patients, 132 were  
219 obese. Of the obese BC patients, 88 were normoglycemic, 48 were pre-diabetic and  
220 33 had DM. The healthy control group had 108 individuals, of which 40 and 68 were  
221 lean and obese, respectively (Table 1a).

#### 222 **3.1. *Clinical and biological analysis of the study population***

223 Various anthropometric parameters, obesity and diabetes factors, and BC clinical  
224 measures, as well as plasma levels of leptin, CD295, ITLN1 were collected (Table  
225 1a), as was information concerning the SNPs under study and DNA damage  
226 parameters for both the BC patients and the healthy controls (Table 1b). There were  
227 significant differences among the measured values between the control and BC group  
228 in terms of polymorphism frequency and DNA damage (see below;  $P \leq 0.05$ ).

229

230

231

232

233

234

235 **Table 1a. Anthropometric parameters, obesity and diabetes factors, and breast**  
236 **cancer clinical factors in breast cancer patients compared to the control group**

Parameter	Control (n=108)	BC patients (n=170)	<i>P-value</i>
Age (years)	53 (43-66)	53 (43-75)	
Insulin ( $\mu$ IU/mL)	8 (4.5-19)	10.6 (3.8-17.3)	0.007
FBG (mg/dL)	100 (66-144)	120 (85-224)	
HOMA-IR index	2.2 (0.81-4.9)	3.4 (0.9-6.6)	0.02
HOMA-B	0.8 (0.31-6)	0.68 (0.13-1.94)	0.03
Obese (-/+)	40/68	38/132	
IR (-/+)	50/58	12/158	
Diabetes (-/pre/+)	90/16/2	88/48/33	
Leptin (ng/mL)	7 (2-11)	15 (8-50)	<0.001
LepR (ng/mL)	22 (11-27)	20 (13-27)	0.001
ITLN1 (ng/mL)	99 (66-177)	40 (30-66)	<0.001
Ejection fraction %		64 (54-80)	
CEA (ng/mL)		4 (1-10)	
CA15.3 (U/mL)		20 (1-126)	
Ki-67		70 (15-80)	
LH (IU/L) <sup>a</sup>		9.9 $\pm$ 0.12	
FSH (mIU/L) <sup>a</sup>		24.5 $\pm$ 1.85	
Estradiol (pg/mL) <sup>a</sup>		27.1 $\pm$ 6.9	
Tumor clinical stage (T) (I/II)		69/101	
Lymph node status (N) (-/+)		66/104	
Metastasis (M) (-/+)		170/0	
Tumor histological grades (II/III)		141/29	
BIRAD (III/IV)		42/128	

237 Data are median (range), statistical analysis was performed using Mann–Whitney U  
238 test,

239 <sup>a</sup> data are mean  $\pm$  S.D, statistical analysis was performed using Chi-square test.

240 FBG; fasting blood glucose, HOMA-IR; homeostasis model assessment-insulin  
241 resistance, CEA; carcinoembryonic antigen, CA 15.3; cancer antigen 15.3, LH;  
242 luteinizing hormone, FSH; follicle stimulating hormone.  
243

244

245

246

247

248 **Table 1b. Studied SNPs and DNA damage parameters of breast cancer patients**  
249 **compared to the control group**

Groups(n)/ parameters	Control (n=108)	BC (n=170)	<i>P-value</i>
<b>CD295 rs6700986 <sup>a</sup></b>			
<b>Genotype</b>			
Homozygous wild-type TT	94	36	0.04
Homozygous mutant-type CC	5	53	<0.001
Heterozygous mutant-type CT	9	81	0.007
CC+CT	14	134	<0.001
<b>ITLN1 rs952804 <sup>a</sup></b>			
<b>Genotype</b>			
Homozygous wild-type CC	84	46	0.037
Homozygous mutant-type TT	15	48	0.001
Heterozygous mutant-type CT	9	76	<0.001
TT+CT	24	124	<0.001
<b>DNA damage</b>			
<b>Tail intensity (%)</b>	2 (1-4)	13 (8-19)	0.001
<b>Tail length (µm)</b>	0.7 (0.53-0.86)	3.5 (2.7-4.34)	0.001
<b>Tail DNA (%)</b>	1.3 (0.9-1.84)	3.95 (2.45-4.97)	0.02
<b>Tail moment unit</b>	3 (2.4-5.4)	12 (9.27-17)	0.001

250 Data are median (range); statistical analysis was performed using Mann–Whitney U

251 test,

252 <sup>a</sup>discrete data are given as numbers; statistical analysis was performed using Chi-  
253 square test. ITLN1; intelectin-1, CD295; cluster of differentiation 295.

### 254 **3.2. Distribution of CD295 and ITLN1 genotypes**

255 *CD295* wild homozygous genotype (TT) was detected in almost all controls (94/108;  
256 87%), but only 36 (21%) BC patients carried this genotype (Table 1b). Meanwhile,  
257 mutant homozygous (CC) and heterozygous (CT) *CD295* genotypes were seen in 53  
258 (31.1%) and 81 (47.6) BC cases, respectively. For *ITLN1*, the wild homozygous  
259 genotype (CC) was detected in the majority of the control subjects (77.7%), whereas  
260 46 (43%) of BC patients carried this genotype (Table 1b). Mutant homozygous (TT)  
261 and heterozygous (CT) genotypes were reported in 48 (28.2%) and 76 (44.7%) BC  
262 cases, respectively.

263                    3.3.            *Distribution of the studied SNPs genotypes among the BC*  
264                                    *patient clinicopathological factors*

265    Stratification of the BC group according to FSH (mIU/L) values revealed that the  
266    *CD295* rs6700986 mutant homozygous (CC) and heterozygous (CT) genotype was  
267    significantly associated ( $P \leq 0.05$ ) with BC cases that had FSH values  $> 25$  mIU/L. A  
268    similar association was seen for BC patients who were heterozygous for the *ITLNI*  
269    rs952804 mutation (CT) (Table 2). HER2/Neu cancer cases with a +3 score had a  
270    significantly higher frequency of mutant homozygous (CC) and heterozygous (CT)  
271    *CD295* rs6700986 genotypes compared to those who had the wild homozygous (TT)  
272    genotype ( $P \leq 0.05$ ). Similar results were also seen for *ITLNI* rs952804 mutant  
273    heterozygous cases (CT).

274    Tumor clinical stage T II and positive LN involvement as well as tumor histologic  
275    grade III were associated with *CD295* rs6700986 mutant homozygous (CC) and  
276    heterozygous (CT) genotypes, as well as *ITLNI* rs952804 mutant heterozygous cases  
277    (CT) ( $P \leq 0.05$ ; Table 2).

278 **Table 2. Distribution of CD295 SNP rs6700986 and ITLN1 SNP rs952804 genotypes among clinicopathological factors for breast cancer**  
 279 **patients (n=170).**

SNP		CD295 rs6700986				ITLN1 rs952804			<i>P-value</i> ***
		TT n (%)	CC n (%)	CT n (%)	<i>P-value</i> ***	CC n (%)	CT n (%)	TT n (%)	
<b>Breast cancer</b>	<b>Lt</b>	31 (25.2)	40 (32.5)	52 (42.3)	0.035	33 (26.8)	56 (45.5)	34 (27.6)	
	<b>Rt</b>	5 (10.9)	12 (26.1)	29 (63)		13 (28.3)	19 (41.3)	14 (30.4)	
<b>FSH (mIU/L)</b>	<b>&lt; 25</b>	33 (49.3)	33 (49)	68 (51)		18 (39.1)	23 (30.7)	19 (39.6)	
	<b>&gt; 25</b>	3 (8.6)	19 (54.3)	13 (37)	0.014	28 (60.9)	52 (69.3)	29 (60.4)	0.016
<b>HER2/Neu</b>	<b>0-1+</b>	24 (35.3)	12 (17.6)	32 (47.1)		29 (63)	24 (32)	15 (31.3)	
	<b>2+</b>	4 (7.1)	21 (37.5)	31 (55.4)		7 (15.2)	31 (41.3)	18 (37.5)	
	<b>3+</b>	8 (17.8)	19 (42.2)	18 (40)	0.001	10 (21.7)	20 (26.7)	15 (31.3)	0.004
<b>Tumor clinical stage (T)</b>	<b>I</b>	13 (19.1)	24 (35.3)	31 (45.6)		18 (26.5)	21 (30.9)	29 (42.6)	
	<b>II</b>	23 (22.8)	28 (27.7)	50 (49.5)		28 (27.7)	54 (53.5)	19 (18.8)	0.002
<b>Lymph node status (N)</b>	<b>-</b>	19 (28.8)	13 (19.7)	34 (51.5)		26 (39.4)	28 (42.4)	12 (18.2)	
	<b>+</b>	17 (16.5)	39 (37.9)	47 (45.6)	0.024	20 (19.4)	47 (45.6)	36 (35)	0.007*
<b>Tumor histological grade</b>	<b>II</b>	33 (23.4)	45 (31.9)	63 (44.7)		41 (29.1)	59 (41.8)	41 (29.1)	
	<b>III</b>	3 (10.7)	7 (25)	18 (64.3)	0.032**	5 (17.9)	16 (57.1)	7 (25)	0.027

280 For FSH the best cutoff value (=25) was calculated by ROC curve.

281 \* CC different from TT, \*\* CT different from TT, \*\*\* CT different from CC

282 ITLN1; intelectin-1, FSH; follicle stimulating hormone, CD295; cluster of differentiation 295.

283                    **3.4.            *Distribution of CD295 rs6700986 and ITLN1 rs95280***

284                    ***genotype variants among BC patient obesity/IR factors***

285    The presence of obesity, IR or DM, as well as having experienced a pre-diabetic event  
286    were associated with mutant homozygous (CC) (for obesity and IR only) and  
287    heterozygous (CT) *CD295* rs6700986 genotypes ( $P \leq 0.05$ ; Table 3). Also, obesity,  
288    pre-diabetic event and being diabetic, in addition to IR were associated with BC cases  
289    that were *ITLN1* rs952804 mutant heterozygous (CT) ( $P \leq 0.05$ ; Table 3).

290                    **3.5.            *Association between CD295 rs6700986 and ITLN1rs952804***

291                    ***polymorphism and anthropometric parameters of BC patients***

292    Mutant homozygous (CC) and heterozygous (CT) genotypes for *CD295* rs6700986  
293    and *ITLN1* rs952804 mutant homozygous (TT) and heterozygous cases (CT) were  
294    significantly ( $P \leq 0.05$ ) associated with higher age (median 54, 53, respectively) for  
295    both SNPs tested (Table 4). This association also occurred for BC patients who had  
296    decreased plasma CEA (ng/mL) levels, increased insulin ( $\mu$ IU/mL) levels, IR, or  
297    increased plasma leptin (ng/mL) levels (Table 4).

298                    **3.6.            *Relationship between studied SNPs CD295 rs6700986 and***

299                    ***ITLN1 rs952804 genotypes and DNA damage parameters***

300    Among DNA damage parameters, only tail DNA (%) and tail moment unit were  
301    significantly ( $P \leq 0.05$ ) associated with *CD295* rs6700986 mutant heterozygous (CT)  
302    genotype and *ITLN1* rs952804 mutant homozygous (TT) genotype (Table 5).

303

304

305

306

307 **Table 3. Distribution of genotype variants of CD295 rs6700986 and ITLN1 rs952804 SNPs among obesity/IR factors in breast cancer**  
 308 **patients (n=170)**

SNP		CD295 rs6700986				ITLN1 rs952804			
		TT n (%)	CC n (%)	CT n (%)	<i>P-value</i> *	CC n (%)	CT n (%)	TT n (%)	<i>P-value</i> ***
<b>Obesity</b>	<b>Event (-)</b>	8 (21.1)	6 (15.8)	24 (63.2)	0.05**	11 (28.9)	18 (47.4)	9 (23.7)	0.05
	<b>Event (+)</b>	28 (21.4)	46 (35.1)	58 (43.5)		35 (26.7)	57 (43.5)	40 (29.8)	
<b>Diabetes</b>	<b>Event (-)</b>	20 (22.7)	27 (30.7)	41 (46.6)	0.05	27 (30.7)	32 (36.4)	29 (33)	0.03
	<b>Event (pre)</b>	9 (18.8)	14 (29.2)	25 (52.1)		11 (22.9)	23 (47.9)	14 (29.2)	
	<b>Event (+)</b>	7 (21.2)	11 (33.3)	15 (45.5)		0.04	8 (24.2)	20 (60.6)	
<b>Insulin resistance</b>	<b>Event (-)</b>	10 (90.9)	1 (9.1)	0 (0)	0.01**	11 (100)	0 (0)	0 (0)	0.01
	<b>Event (+)</b>	26 (16.5)	51 (32.3)	81 (51.3)		35 (22.2)	75 (47.5)	48 (30.4)	

309 Data are number (%), significant at ( $P \leq 0.05$ ) using Chi-square test.

310 \* CT different from TT, \*\* CC different from TT, \*\*\* CT different from CC.

311

312

313

314

315

316 **Table 4. Association between CD295 rs6700986 and ITLN1rs952804 polymorphisms and anthropometric parameters in breast cancer**  
 317 **patients (n=170)**

SNP Parameters	CD295 rs6700986			<i>P-value</i> ***	ITLN1 rs952804			<i>P-value</i> **,**
	TT	CC	CT		CC	CT	TT	
<b>Age (years)</b>	50 (47-64)	54 (43-75)	53 (46-75)	0.05	50 (47-75)	53 (45-75)	54 (43-75)	0.001***
<b>CEA (ng/mL)</b>	4.5 (1-10)	3.5 (1-10)	4 (1-10)	0.029	9 (1-10)	4 (1-10)	3.8 (1-10)	0.003
<b>Insulin (μIU/mL)</b>	7.2 (3.8-16.1)	13.7 (4.9-17.3)	10.4 (5.1-15.8)	0.001	8.1 (3.8-13.1)	10.4 (6-15.8)	14.4 (9.5-17.3)	0.001
<b>HOMA-IR</b>	2.4 (0.9-4.5)	3.8 (1.2-6.6)	3.3 (2.5-4.3)	0.001	2.5 (0.9-3.2)	3.4 (2.7-4.1)	4 (3.4-6.6)	0.0001
<b>Leptin (ng/mL)</b>	15 (8-19)	16 (11-50)	15 (8-20)	0.003**	15 (8-20)	15 (8-50)	16 (11-25)	0.015**

318 Data are median (range), significant at  $P \leq 0.05$  using Chi-square test.

319 \* CT different from TT, \*\* CC different from TT, \*\*\* CT different from CC.

320 HOMA-IR; homeostasis model assessment-insulin resistance, ITLN1; intelectin-1, CEA; carcinoembryonic antigen, CD295; cluster of  
 321 differentiation 295.

322

323

324

325

326

327 **Table 5. Genotype distribution of CD295 rs6700986 and ITLN1 rs952804 SNPs relative to DNA damage parameters in breast cancer**  
 328 **patients (n=170)**

SNPs/ DNA damage	CD295 rs6700986			<i>P-value*</i>	ITLN1 rs952804			<i>P-value**</i>
	TT	CC	CT		CC	CT	TT	
<b>Tailed (%)</b>	13 (8-19)	13 (8-17)	13 (8-19)		13 (8-19)	13 (8-19)	13 (8-17)	
<b>Tail length (µm)</b>	3.8 (2.7-4.3)	3.4 (3-4.3)	3.5 (2.7-4.3)		3.6 (2.7-4.3)	3.6 (2.7-4.3)	3.5 (3-4.3)	
<b>Tail DNA (%)</b>	3.7 (2.5-5)	4 (2.5-5)	3.5 (2.5-5)	0.043	4 (2.5-5)	4 (2.5-5)	3.4 (2.5-5)	0.029
<b>Tail moment unit</b>	12.2 (9.3-17)	12.2 (10-17.1)	11.6 (9.3-17)	0.031	12.2 (10-17.1)	12.2 (10-17.1)	11 (9.3-16.1)	0.016

329 Data are median (range), significant at  $P \leq 0.05$  using Chi-square test.

330 \* CT different from TT, \*\* TT different from CC.

331

332                    **4. DISCUSSION**

333        The results of our study on a population of BC patients in Egypt demonstrated that the  
334        *CD295* gene is highly polymorphic among BC patients. We found that *CD295*  
335        polymorphisms were associated with BC cases having late TN classification, as well  
336        as FSH levels > 25 mIU/L and HER2/Neu score of +3. Furthermore, BC patients who  
337        were obese, diabetic, or pre-diabetic were more likely to carry type I cytokine  
338        receptor; leptin receptor (LEP-R) *CD295* polymorphisms. Those patients who had  
339        mutant homozygous (CC) or heterozygous (CT) *CD295* rs6700986 genotypes had a  
340        higher incidence of tumor clinical stage T II, positive LN involvement, histologic  
341        grade III, obesity, pre-diabetes, IR or DM. The CD295 protein is encoded by a gene  
342        belonging to the 130-member family of glycoprotein cytokine receptors that are  
343        known to enhance gene transcription by activating cytosolic STAT proteins (Vona-  
344        Davis and Rose 2007). In addition to functioning in hemoatopoietic pathways that are  
345        required for lymphopoiesis, CD295 functions as a receptor for leptin, a hormone that  
346        acts on adipocytes to regulate body weight (Wauman et al 2017). Indeed, mutations in  
347        the gene that encodes leptin have been related to an increased frequency of obesity  
348        (Mahmoudi et al 2015). Moreover, leptin plays a role in cell growth and  
349        differentiation, as well as angiogenesis by promoting increased production of  
350        signaling molecules such as NO, VEGF, FGF2, and VEGFR2 by endothelial cells  
351        (Gonzalez et al 2006). In cancer, leptin is considered to act as both a mitogenic and  
352        migration factor in malignant cells (Choi et al 2005). In the context of BC, however,  
353        Woo et al (2006) found no significant connection between four polymorphisms in the  
354        leptin receptor gene and the risk of BC. They likewise did not observe noteworthy  
355        differences in serum leptin levels between BC patients and controls. We also  
356        examined the emerging role of *ITLNI* SNPs in BC, and found that rs952804

**Hamdy and El-Shemy 2020**

357 polymorphisms were related to BC risk factors (grade III, positive LN involvement)  
358 as well as to the presence of obesity, IR, DM, and pre-diabetes. These findings are  
359 consistent with earlier reports showing that *ITLN1* participates in immune defense  
360 and insulin-stimulated glucose uptake in human subcutaneous and omental adipocytes  
361 (Li et al 2015). In particular, BC cases that were heterozygous for the *ITLN1*  
362 rs952804 mutant (CT) were significantly associated with tumor clinical stage T II and  
363 positive LN involvement as well as tumor histologic grade III, presence of obesity,  
364 pre-diabetic event, DM and IR ( $P \leq 0.05$ ). Relative to the adipokine vaspin, *ITLN1*  
365 levels appear to give be superior indicators of IR among obese patients in the study  
366 group by Sperling et al (2016). Obesity is an important health problem, and is  
367 positively correlated with the occurrence and mortality of BC (Lorincz and Sukumar  
368 2006, Chu et al 2019). Moreover, obese BC patients are known to have a higher risk  
369 of LN metastasis, larger tumors, and higher death rates compared with non-obese  
370 patients (Rose and Vona-Davis 2010). These increased risks might be due to elevated  
371 estrogen levels that occur from enhanced aromatization in adipose tissue and  
372 increases in the levels of mitogenic agents such as insulin and/or IGF associated with  
373 obesity-related metabolic syndromes (DM and BC) (Erbay et al 2016). In addition to  
374 increased estrogen levels, increases in insulin levels may also contribute to the  
375 development of BC by enhancing insulin-like growth factor-I (IGF-1) receptor-  
376 mediated release of VEGF from breast tissues (Erbay et al 2016), which could couple  
377 with effects associated with increased leptin levels (Belfiore 2007). Moreover, the  
378 adverse influence of DM on the prognosis of cancer patients with malignancies is  
379 likely associated with effects of insulin on the tyrosine kinase growth receptor  
380 pathway (Belfiore 2007). Insulin, IGF-I, and hybrid IGF-I/insulin receptors, are all  
381 overexpressed in BC cells (DeCensi and Gennari 2011). As such, activation of these

**Hamdy and El-Shemy 2020**

382 receptors could up-regulate expression of insulin receptor substrate 2 that in turn  
383 activates downstream MAPK and phosphatidylinositol 3-kinase-Akt pathways  
384 (Belfiore 2007). Indeed, *in vitro* studies demonstrated that *ITLN1* increases insulin  
385 signal transduction by activating protein kinase Akt/protein kinase B signaling and  
386 enhancing insulin-stimulated glucose transport in isolated human adipocytes.  
387 Increased BC risk related to hyperinsulinemia could be attributed to a synergistic  
388 interaction between elevated free estrogen concentrations and aberrant insulin  
389 signaling. Furthermore, the ability of *ITLN1* to activate AKT, a key survival factor,  
390 could be a mechanism for *ITLN1*-mediated cell proliferation in BC (Bahadori et al  
391 2014). This effect, together with *CD295* stimulation of gene transcription associated  
392 with activation of cytosolic JAK-STAT proteins, MAPK, PI3K, and AMPK  
393 (Mahmoudi et al 2015), may contribute to the increased frequency of *ITLN1* and  
394 *CD295* polymorphisms seen in this study. It should be noted that *ITLN1* rs952804  
395 mutant heterozygous (CT), specifically the T allele, was related to BC risk, DNA  
396 damage and obesity, DM and IR. In addition, there was no statistically significant  
397 difference between our observations and that predicted by the Hardy-Weinberg  
398 principle for *ITLN1*, suggesting that the population was in Hardy-Weinberg  
399 equilibrium (HWE) (data not shown). Thus, the null hypothesis is *not* rejected, and  
400 we presume that the population is indeed in HWE, although additional study is  
401 needed to contrast the findings for this locus with that of another study population.  
402 There is currently no BC screening program in Egypt and in the absence of  
403 population-based-cancer registries in developing nations, including Egypt, patients  
404 with early pre-clinical illness may have been missed in our study. It is possible that  
405 polymorphisms of *CD295* or potentially *ITLN1* could contribute to variations in BC

**Hamdy and El-Shemy 2020**

406 occurrence. Nonetheless, in this study SNPs in *CD295* and *ITLNI* were related to  
407 oxidative stress/DNA damage in postmenopausal Egyptian female BC patients.

408 **5. Conclusions.** This study showed an increased risk of BC in women  
409 carrying the C allele of the *CD295* rs6700986 polymorphism and the T allele of the  
410 *ITLNI* rs952804 polymorphism. Our results suggest that these SNPs could be  
411 considered as BC-related risk factors.

412

413 **RECOMMENDATIONS.** *ITLNI* and *CD295* polymorphism testing could be used to  
414 assess BC susceptibility in either obese or insulin resistant, pre-diabetic patients. We  
415 therefore suggest that this high-risk BC population be screened for these SNPs.

416

417 **Author contribution.** Authors contributed equally to all aspects of this study,  
418 including data collection and analysis and drafting of the manuscript.

419 **Conflict of Interest.** None to Declare.

420 **Funding.** This research received no specific grant from funding agencies in the  
421 public, commercial, or not-for-profit sectors.

422

## 423 **6. REFERENCES**

424 **Adeloye D, Sowunmi OY, Jacobs W, et al. 2018.** Estimating the incidence of breast  
425 cancer in Africa: a systematic review and meta-analysis. *J Glob Health*; 8(1):010419.

426 **Bahadori M, Kohan L, Farzan M, Aliakbari S, Panah MM. 2014.** An increased  
427 risk of breast cancer associated with Val109Asp polymorphism in omentin gene.  
428 *International Journal of Biosciences* 5(1): 429-434.

429 **Belfiore A. 2007.** The Role of Insulin Receptor Isoforms and Hybrid Insulin/IGF-I  
430 Receptors in Human Cancer 13(7): 671 – 686.

**Hamdy and El-Shemy 2020**

- 431 **Boyd DB. 2003.** Insulin and Cancer. *Integrative Cancer Therapies* 2(4):315 – 329.
- 432 **Choi J-H, Park S-H, Leung PCK, and Choi K-C. 2005.** Expression of leptin  
433 receptors and potential effects of leptin on the cell growth and activation of mitogen-  
434 activated protein kinases in ovarian cancer cells,” *e Journal of Clinical Endocrinology*  
435 *& Metabolism* 90(1):207–210.
- 436 **Chu DT, Phuong TNT, Tien NLB, et al. 2019.** The Effects of Adipocytes on the  
437 Regulation of Breast Cancer in the Tumor Microenvironment: An  
438 Update. *Cells*;8(8):857.
- 439 **DeCensi A, Gennari A. 2011.** Insulin breast cancer connection: confirmatory data set  
440 the stage for better care. *J Clin Oncol* 29(1):7-10.
- 441 **Du Y, Ji Q, Cai L, Huang F, Lai Y, Liu Y, Yu J, Han B, Zhu E, Zhang J, Zhou**  
442 **Y, Wang Z, Zhao Y. 2016.** Association between omentin-1 expression in human  
443 epicardial adipose tissue and coronary atherosclerosis. *Cardiovascular*  
444 *Diabetology* 15:90.
- 445 **Erbay B, Yilmaz TU, Eraldemir C, et al. 2016.** The Relationship between  
446 Adiponectin and Breast Cancer. *The Journal of Breast Health* 12(2):67-71.
- 447 **Galardi F, Oakman C, Truglia MC, Cappadona S, Biggeri A, Grisotto L,**  
448 **Giovannelli L, Bessi S, Giannini A, Biganzoli L, Santarpia L, Di Leo A. 2012.**  
449 Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in  
450 early breast cancer patients. *Breast* 21(3):336-42.
- 451 **Gonzalez RR, Cher S, Escobar M. et al. 2006.** Leptin signaling promotes the  
452 growth of mammary tumors and increases the expression of vascular endothelial  
453 growth factor (VEGF) and its receptor type two (VEGF-R2), *e Journal of Biological*  
454 *Chemistry* 281(36): 26320–26328.

**Hamdy and El-Shemy 2020**

- 455 **Heid CA, Stevens J, Livak KJ and Williams PM. 1996.** Real time quantitative  
456 PCR. *Genome Res* 6:986–994.
- 457 **Huang C-J, Slusher AL, Whitehurst M, Wells M, Maharaj A and Shibata Y.**  
458 **2016.** The impact of acute aerobic exercise on chitinase 3-like protein 1 and  
459 intelectin-1 expression in obesity. *Experimental Biology and Medicine* 241(2): 216–  
460 221.
- 461 **Ibarra-Drendall C, Dietze EC and Seewaldt VL. 2011.** Metabolic Syndrome and  
462 Breast Cancer Risk: Is There a Role for Metformin? *Curr Breast Cancer Rep* 3:142–  
463 150.
- 464 **Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. 2014.** Cancer  
465 Incidence in Egypt: Results of the National Population-Based Cancer Registry  
466 Program. *Journal of Cancer Epidemiology* 2014:437971.
- 467 **Imayama I, Alfano CM, Neuhaus ML, et al. 2013.** Weight, inflammation, cancer-  
468 related symptoms and health-related quality of life among breast cancer  
469 survivors. *Breast Cancer Research and Treatment* 140(1):159–176.
- 470 **Jamshidi J, Ghanbari M, Asnaashari A, Jafari N, Valizadeh GA. 2017.** Omentin  
471 Val109Asp polymorphism and risk of coronary artery disease. *Asian Cardiovascular*  
472 *Thoracic Annals* 25(3):199-203.
- 473 **Laschober GT, Brunauer R, Jamnig A, Fehrer C, Greiderer B, Lepperdinger G.**  
474 **2009.** Leptin receptor/CD295 is upregulated on primary human mesenchymal stem  
475 cells of advancing biological age and distinctly marks the subpopulation of dying  
476 cells. *Experimental Gerontology* 44(1-2):57–62.
- 477 **Li D, Mei H, Pu J, et al. 2015.** Intelectin 1 suppresses the growth, invasion and  
478 metastasis of neuroblastoma cells through up-regulation of N-myc downstream  
479 regulated gene 2. *Molecular Cancer* 14:47.

**Hamdy and El-Shemy 2020**

- 480 **Lorincz AM, Sukumar S. (2006)** Molecular links between obesity and breast cancer.  
481 *Endocr Relat Cancer* 13:279-292.
- 482 **Mahmoudi R, Noori Alavicheh B, Nazer Mozaffari MA, Fararouei M,**  
483 **Nikseresht M. 2015.** Polymorphisms of Leptin (-2548 G/A) and Leptin Receptor  
484 (Q223R) Genes in Iranian Women with Breast Cancer. *International Journal of*  
485 *Genomics* 2015:132720.
- 486 **Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF and Turner**  
487 **RC. 1985.** Homeostasis model assessment: insulin resistance and beta cell function  
488 from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 28:412–  
489 419.
- 490 **Miehle K, Stepan H and Fasshaauer M. 2012.** Leptin, adiponectin, and other  
491 adipokines in gestational diabetes mellitus and pre-eclampsia. *ClinEndocrinolo.* 76:2-  
492 11.
- 493 **Nasiri AR, Rodrigues MR, Li Z, Leitner BP, Perry RJ. 2019.** SGLT2 inhibition  
494 slows tumor growth in mice by reversing hyperinsulinemia. *Cancer Metab.;*7:10.
- 495 **Rose DP and Vona-Davis L. 2010.** Interaction between menopausal status and  
496 obesity in affecting breast cancer risk. *Maturitas* 66:33-38.
- 497 **Singh NP, McCoy MT, Tice RR, Schneider EL. 1988.** A simple technique for  
498 quantitation of low levels of DNA damage in individual cells. *Experimental Cell*  
499 *Research* 175(1):184-191.
- 500 **Sperling M, Grzelak T, Pelczyńska M, Jasinska P, Bogdanski P, Pupek-Musialik**  
501 **D, Czyzewska K. 2016.** Concentrations of omentin and vaspin versus insulin  
502 resistance in obese individuals. *Biomed Pharmacother* 83:542-547.
- 503 **Stender JD, Nwachukwu JC, Kastrati I, Kim Y, Strid T, Yakir M, Srinivasan S,**  
504 **Nowak J, Izard T, Rangarajan ES, Carlson KE, Katzenellenbogen JA, Yao XQ,**

**Hamdy and El-Shemy 2020**

- 505 **Grant BJ, Leong HS, Lin CY, Frasor J, Nettles KW, Glass CK. 2017.** Structural  
506 and Molecular Mechanisms of Cytokine-Mediated Endocrine Resistance in  
507 Human Breast Cancer Cells. *Mol Cell*. 65(6):1122-1135.e5
- 508 **Vona-Davis L. and Rose DP. 2007.** Adipokines as endocrine, paracrine, and  
509 autocrine factors in breast cancer risk and progression. *Endocrine-Related Cancer*  
510 14(2):189–206.
- 511 **Wallace TM, Levy JC, Matthews DR. 2004.** Use and Abuse of HOMA Modeling.  
512 *Diabetes Care* 27(6):1487-1495.
- 513 **Wauman J, Zabeau L, Tavernier J. 2017.** The Leptin Receptor Complex: Heavier  
514 Than Expected?. *Front Endocrinol (Lausanne)*;8:30.
- 515 **WMA. 2013.** 64th World Medical Association General Assembly, Fortaleza, Brazil,  
516 October 2013. <http://www.wma.net/en/30publications/10policies/b3>.
- 517 **Woo H-Y, Park H, Ki C-S, Park YL, and Bae WG. 2006.** Relationships among  
518 serum leptin, leptin receptor gene poly- morphisms, and breast cancer in Korea,  
519 *Cancer Letters* 237(1):137–142.